Список проголосовавших за комментарий " <table class="BriefingDataTable" border="0" cellspacing="0" cellpadding="0"><tr> <td class="tickerColumn"> </td> <td class="articleColumn">On The Wires<ul><li>Trillium Therapeutics (<strong>TRIL</strong>) announced that it will present new data from the Phase 1 trial of its anti-CD47 checkpoint inhibitor TTI-621 at the ASCO-SITC Clinical Immuno-Oncology Symposium on February 24, in Orlando, Florida.</li><li>Medicines360 and Allergan plc (<strong>AGN</strong>) announced a partnership with 340B-eligible health centers and other safety net providers in Puerto Rico and Florida, both areas where there is local transmission of the Zika virus, to make available their hormonal contraceptive, LILETTA (levonorgestrel-releasing intrauterine system) 52 mg. LILETTA is an IUS, intrauterine system (otherwise known as an intrauterine device or IUD), that is approved for the prevention of pregnancy for up to three years. Research has shown that pregnant women infected with the Zika virus are at risk of giving birth to infants born with microcephaly — a birth defect caused by the exposure to the Zika virus where a baby's head is smaller than expected when compared to babies of the same sex and age. LILETTA, is available at a lower cost to public health clinics enrolled in the 340B Drug Pricing Program.</li><li>Amunix Operating announced that it has entered into a research and development collaboration with Genentech, a member of the Roche Group (<strong>RHHBY</strong>). The agreement will focus on the discovery and development of therapeutics utilizing Amunix's proprietary XTEN technology against multiple targets selected by Genentech.</li><li>FLIR Systems (<strong>FLIR</strong>) awarded a $50 mln IDIQ contract to provide marine electronics systems under the U.S. Coast Guard's Scalable Integrated Navigation Systems 2 (SINS-2) program over a five-year period providing the purchaser a right to extend delivery for an additional five years. FLIR will provide electronics systems that will be standard fit on over 2,000 U.S. Coast Guard vessels, ranging from small-class boats through large cutter-class vessels.</li><li>Novocure (<strong>NVCR</strong>) announced that the first patient has been enrolled in LUNAR, its phase 3 pivotal trial of Tumor Treating Fields at 150 kHz as a treatment for advanced non-small cell lung cancer after failing platinum-based therapy.</li></ul></td> </tr></table>"